Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus

被引：53

作者：

Cuenca-Estrella, M ^{[1
]}

Gomez-Lopez, A ^{[1
]}

Garcia-Effron, G ^{[1
]}

Alcazar-Fuoli, L ^{[1
]}

Mellado, E ^{[1
]}

Buitrago, MJ ^{[1
]}

Rodriguez-Tudela, JL ^{[1
]}

机构：

[1] Inst Salud Carlos III, Ctr Nacl Microbiol, Serv Micol, Majadahonda 28220, Spain

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2005年 / 49卷 / 03期

关键词：

D O I：

10.1128/AAC.49.3.1232-1235.2005

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Interactions in vitro between amphotericin B, itraconazole, voriconazole, and caspofungin against itraconazole-resistant Aspergillus fumigatus clinical strains were determined. Differential results were obtained depending on the criteria (MIC or minimal effective concentration) used. Caspofungin and voriconazole exhibited the most potent interactions, with synergy against at least 50% of isolates, and the average fractional concentration index was 0.38. Antagonism was not found for any combination.

引用

页码：1232 / 1235

页数：4

共 34 条

[1] In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B [J].

Abraham, OC ;

Manavathu, EK ;

Cutright, JL ;

Chandrasekar, PH .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1999, 33 (01) :7-11

[2] Refractory aspergillus pneumonia in patients with acute leukemia - Successful therapy with combination caspofungin and liposomal amphotericin [J].

Aliff, TB ;

Maslak, PG ;

Jurcic, JG ;

Heaney, ML ;

Cathcart, KN ;

Sepkowitz, KA ;

Weiss, MA .

CANCER, 2003, 97 (04) :1025-1032

[3] In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. [J].

Arikan, S ;

Lozano-Chiu, M ;

Paetznick, V ;

Rex, JH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :245-247

[4] In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872) [J].

Bartizal, K ;

Gill, CJ ;

Abruzzo, GK ;

Flattery, AM ;

Kong, L ;

Scott, PM ;

Smith, JG ;

Leighton, CE ;

Bouffard, A ;

Dropinski, JF ;

Balkovec, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2326-2332

[5] Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukaemia or undergoing allogeneic bone marrow transplant [J].

Castagnola, E ;

Machetti, M ;

Cappelli, B ;

Molinari, AC ;

Morreale, G ;

Dodero, P ;

Toma, P ;

Faraci, M .

CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (03) :255-257

[6] In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. Acquired resistance to itraconazole [J].

Chryssanthou, E .

SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1997, 29 (05) :509-512

[7] Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp. [J].

Cuenca-Estrella, M ;

Díaz-Guerra, TM ;

Mellado, E ;

Rodríguez-Tudela, JL .

JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (02) :525-532

[8]

CUENCAESTRELLA M, 2003, ADV STUD MED, V3, pS14

[9] Rapid improvement of disseminated aspergillosis with caspofungin/voriconazole combination in an adult leukemic patient [J].

Damaj, G ;

Ivanov, V ;

Le Brigand, B ;

D'incan, E ;

Doglio, MF ;

Bilger, K ;

Faucher, C ;

Vey, N ;

Gastaut, JA .

ANNALS OF HEMATOLOGY, 2004, 83 (06) :390-393

[10] In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis [J].

Dannaoui, E ;

Borel, E ;

Persat, F ;

Monier, MF ;

Piens, MA .

JOURNAL OF MEDICAL MICROBIOLOGY, 1999, 48 (12) :1087-1093

← 1 2 3 4 →